Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Brief Summary: The trial will compare the drugs olaparib and cediranib with standard chemotherapy in platinum resistant ovarian cancer. Patients will be randomised to one of three treatment groups: olaparib only, olaparib and cediranib and the control group paclitaxel. The aim is to compare efficacy of the 3 treatments and also how well each treatment is tolerated including the participants quality of life.


Options:
A: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib
B: Arm Label: Lead-in Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Extension - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: A. Non-Randomized Expansion (NRE) Cohort - Ovarian; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): A. Non-Randomized Expansion (NRE) Cohort - Ovarian, Lead-in Stage - cabozantinib (XL184), Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg, Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg, Open-Label Extension - cabozantinib (XL184), Randomized Stage - cabozantinib (XL184) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Stage - placebo
C: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
D: Arm Label: Carboplatin + Paclitaxel + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab

Answer: C